Results 111 to 120 of about 20,576 (195)

Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration. [PDF]

Invest Ophthalmol Vis Sci
Shi J, Xu H, Zhao H, Zhao J, Chen L, Xu P, Jia D, Jiang C.   +7 more
europepmc   +1 more source

Intravitreal aflibercept (Eylea) injection for cystoid macular edema secondary to retinitis pigmentosa - a first case report and short review of the literature [PDF]

, 2015

core   +1 more source

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis

Clinical Ophthalmology
Hazem Saleh Aljuhani,1,* Rahaf A Hubayni,2,3,* Jumanah Qedair,2,3 Ziad M Bukhari,4 Ahmed Alzahrani,4 Razan Osama Bawazir,2,3 Orjwan Salah Badghaish,2,3 Faisal Alqahtani5 1Ophthalmology Department, Jeddah Eye Hospital, Jeddah, Saudi Arabia;
Aljuhani HS, Hubayni RA, Qedair J, Bukhari ZM, Alzahrani A, Bawazir RO, Badghaish OS, Alqahtani F   +7 more
doaj  

Clinical Outcomes of High-Dose Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Bousamri A, Al-Shehri M, Mestarihi M, Almutairi TB, Alaredhi M, Mahanna B, Alharbi F.   +6 more
europepmc   +1 more source

One-Year Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in Japan: A Multicenter Retrospective Study. [PDF]

Clin Ophthalmol
Mizuma R, Mizuki Y, Kamata A, Onishi J, Sakono T, Suzuki M, Mizuki N.   +6 more
europepmc   +1 more source

Switching to High-Dose Aflibercept (8 mg) with Pro Re Nata Reduces Treatment Burden in Diabetic Macular Edema: A Real-World Pilot Study. [PDF]

J Clin Med
Funatsu M, Higashijima F, Ariyoshi N, Haraguchi A, Wasai Y, Mikuni M, Ohta M, Wakuta M, Hirano S, Yamauchi K, Kimura K.   +10 more
europepmc   +1 more source

Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME) [PDF]

, 2015

core   +1 more source

Ocular Half-Life: What it Does and Does Not Mean for Intravitreal Anti-angiogenic Drug Durability. [PDF]

Ophthalmol Ther
Avery R, Diack C, Holekamp N, Lhor M, Mar F, Maass K.   +5 more
europepmc   +1 more source

Measurement of Acute Intraocular Pressure Elevation Immediately After Intravitreal Anti-VEGF Injection and Analysis of Prefilled Syringe Accuracy. [PDF]

Clin Ophthalmol
Itoh K, Negishi M.
europepmc   +1 more source

2018 Stuart Rome Lecture: Origins of and Potential Solutions to High Prescription Drug Prices in the U.S. [PDF]

, 2019
Kesselheim, Aaron S.
core   +1 more source